Log-in / Create Account  
Session Information
2007 BIO International Convention
Click here to go to the previous page
'Twinning' Strategies: The Business of Companion Diagnostics and Targeted Therapies
Track : Devices and Predictive Diagnostics
Program Code: DEV020
Date: Sunday, May 6, 2007
Time: 4:00 PM to 5:30 PM  
Location: 205 B
CHAIR :
Ian Nisbet, Vice President Oncology, ChemGenex Pharmaceuticals
SPEAKER (S):
Karl Wassmann
William Welch, Senior Vice President and Chief Commercial Officer, Monogram Biosciences, Inc.
John Tonkinson, PhD, Vice President, Business Development, HistoRx, Inc.
Mara Aspinall, President, Genzyme Genetics
Description
The potential for targeted therapies rests in part on the development of diagnostic products and technologies to identify patients most likely to benefit from a drug treatment. Several companies have taken new approaches to developing successful business models around the marriage of diagnostics to drugs.



Objectives:
  • Outline the various strategies for building a companion diagnostics business.

  • Highlight the potential rewards and risks of this business.

  • Feature current successful business models.

    • Streaming Audio with
    PowerPoint Slides
    (Code: DEV020)
      
    This session is a part of:
    Devices and Predictive Diagnostics 2-DAY TRACK
    Complete Set of BIO Online / CD-ROM - All 23 Tracks.